Showing 1681-1690 of 2006 results for "".
- Life Sciences Industry Eyes $1.5 Trillion Milestonehttps://practicaldermatology.com/news/life-sciences-industry-eyes-15-trillion-milestone/2457703/The life sciences industry is nearing a $1.5 trillion milestone, according to an analysis from Frost & Sullivan. The firm’s Global Life Sciences Industry Outlook, 2018 report finds that healthcare digitization and consumerization, the explosion of patient data, and the emergence of
- Modern Aesthetics® Set to Launch New Tweet Chat Series-- #RealDealAestheticshttps://practicaldermatology.com/news/modern-aesthetics-set-to-launch-new-tweet-chat-series-realdealaesthetics/2457720/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is launching a new Tweet chat series --#RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD. The f
- Xact Nabs Best of Hot Topics at ASAPS 2018https://practicaldermatology.com/news/xact-nabs-best-of-hot-topics-at-asaps-2018/2457727/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (ASAPS) meeting in New York. Xact technology is a minimally invasive face and neck lifting suturing d
- ThermiVa: First-ever Data Show Vaginal Regenerationhttps://practicaldermatology.com/news/thermiva-first-ever-data-show-vaginal-regeneration/2457730/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used
- Galderma Global Survey Assesses Burden of Rosaceahttps://practicaldermatology.com/news/galderma-global-survey-assesses-burden-of-rosacea/2457732/Recently released findings from Galderma’s global survey on the true burden of rosacea suggest a need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea. An expert-authored report entitled Rosacea:
- Luma Therapeutics Launches Novel illuvinate Phototherapy Systemhttps://practicaldermatology.com/news/luma-therapeutics-launches-novel-illuvinate-phototherapy-system/2457736/Luma Therapeutics has launched illuvinate as an innovative and modern twist on the Goeckerman regimen. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globules, illuvinate increases the skin's hydration, decreases inflammation, and suppresses overacti
- Eclipse Announces New Board Membershttps://practicaldermatology.com/news/eclipse-announces-new-board-members/2457740/Meet Eclipse’s Medical and Scientific Advisory Board (M&SAB) for 2018. The 2018 Eclipse M&SAB includes: Dr. Sanjay Batra Dr. Batra obtained his PhD in physiology from the University of Ottawa, C
- Gryphon Investors Makes Majority Investment in Water's Edge Dermatologyhttps://practicaldermatology.com/news/gryphon-investors-makes-majority-investment-in-waters-edge-dermatology/2457741/Gryphon Investors has made a majority investment in Water’s Edge Dermatology. Terms of the transaction were not disclosed. Gryphon Investors is a San Francisco-based middle market private equity firm. A leading provider of comprehensive dermatology services in over 30
- New Dermatologic Surgery Textbook by McGraw-Hill Enters Second Printing Less Than One Week After Publicationhttps://practicaldermatology.com/news/new-dermatologic-surgery-textbook-by-mcgraw-hill-enters-second-printing-less-than-one-week-after-publication/2457746/McGraw-Hill has just released Jonathan Kantor’s new 1,440-page textbook, Dermatologic Surgery, the most comprehensive and richly illustrated dermatologic surgery textbook ever published, and the first new major multimedia textbook in the field in 13 years. With section editors
- FDA Approves Cimzia for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-cimzia-for-moderate-to-severe-plaque-psoriasis/2457747/The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy